Dr. Korina Alevrogianni Does Not Want to Win the Beauty Market, Beauty Health Index (BHI) Wants to Own the Number That Measures It

ATHENS, GA, October 1, 2026 (EZ Newswire) -- Beauty Health Index (BHI) launched publicly on September 15, 2026, entering the market with a peer-reviewed framework, a patent-pending measurement method, and a professional network spanning six cities across three continents. 

The company's proposition is narrower than most consumer health launches and, if it holds, considerably more durable. It is not offering a better face-scanning app. It is proposing that facial aesthetic health become a measurable category, with a defined standard behind it, in a market that has operated without one.

The Founder Built the Measure Instead of Another Practice

BHI was founded by Dr. Korina Alevrogianni, a plastic surgery resident based in Athens who trained in France, Brazil and the United States. She is 29.

The choice she made is the commercially interesting one. A surgeon with that training has an obvious route available, which is to build a practice and compete for patients inside the existing market. Alevrogianni went after the instrument the market uses to judge itself instead, which is a slower business to build and a harder one to displace once it is established.

Behind her is a clinical leadership team drawn from plastic surgery and from the aesthetics technology industry, and the distinction matters for a company making a standards claim. A measurement framework proposed by a single practitioner is a proposal. One carried by a clinical bench with commercialisation experience is a candidate for adoption.

The Method Went to Reviewers Before Anything Went on Sale

The sequence is the company's central credibility argument, and it is unusual in consumer health technology.

Alevrogianni published the framework in Cureus, a peer-reviewed medical journal, where it is indexed on PubMed. The paper constructs the index from a structured review of existing research across aesthetic surgery, dermatology, psychophysiology, regenerative biology and lifestyle medicine.

The framework reads a face across five domains: morphologic harmony, skin quality, expression dynamics, regenerative performance and lifestyle influence. Those resolve into forty evidence-based subsystems, weighted so that no single component dominates the composite score. A 60-second smartphone scan produces a single reading, tracked over time against the user's own prior scans.

The company holds patent-pending status on the underlying method. Validation studies are underway.

The paper is explicit that this is a proposed framework rather than a validated clinical instrument, and the company has been consistent in repeating that distinction. In a category where certainty is routinely asserted and rarely evidenced, publishing the methodology openly and naming what remains unproven is a defensible commercial position rather than a hedge.

That order of operations follows from the argument the company is making. Sleep has a standard. Metabolic health has a standard. Aesthetic medicine has trained practitioners making consequential judgments with no instrument to measure the result, and a standard that outside parties cannot examine does not function as a standard. Publication came first because the framework has to survive inspection before it can ask anyone to adopt it.

An Industry Where Nobody, Not Even the Doctor, Can Prove What Worked

The commercial reasoning behind the category claim rests on a structural gap rather than on consumer demand for another app.

Aesthetic medicine and the consumer skincare market operate at significant scale, and neither has a shared measure of outcomes. Dermatologists grade skin using subjective scales. Surgeons assess proportion in isolation. The before-and-after photograph remains the industry's default evidence, and it varies with lighting, camera angle and the condition of the subject on the day.

What that produces is an industry running on faith at scale. Money moves, treatments are performed, and neither the person paying nor the professional performing the procedure can demonstrate what actually changed. Every other market that reached this size eventually built a measure, because at some point the absence of one becomes the constraint on growth. This one has not been built yet.

BHI is positioned to occupy that gap. The strategic parallel the company draws is to establish measurement standards in other sectors, where the entity that defines the measure occupies a different competitive position from the entities that compete within it.

Why Six Clinics Say More Than a Million Downloads

The company launches with a professional network already established across Beverly Hills, New York, Athens, London, Paris, and Sydney.

For a business readership, this is the more informative signal than user numbers at launch. Consumer adoption can be purchased. Clinical adoption cannot, and practitioners who put a measurement framework in front of their own patients are staking their professional judgment on it.

The network also indicates the intended commercial route. A standard adopted by clinics generates institutional demand rather than consumer demand alone, and institutional adoption is considerably harder to displace.

Free Today, Priced Later, Funded After That

BHI is available on a freemium model. A premium tier is planned to follow the completion of a funding round.

The company has not disclosed pricing for the premium tier or the size of the round it is pursuing.

The Real Test Is Whether Other Companies Start Using the Score

The company's stated ambition is category definition rather than market share, and that ambition carries a specific risk profile.

If the framework achieves adoption by clinicians and by other companies operating in the space, BHI occupies the position of the entity that defined the measure. If it does not, the company has built a consumer application in a crowded category with a peer-reviewed paper behind it, which is a stronger position than most competitors hold but a materially smaller one than the ambition implies.

The determining factors over the next twelve months are the outcome of the validation studies, whether the professional network expands beyond its founding six cities, and whether any third party adopts the framework independently. That last measure is the clearest signal of a standard taking hold, and it is the one worth watching.

About Beauty Health Index

Beauty Health Index (BHI) is a facial aesthetic health measurement company founded by Dr. Korina Alevrogianni, a plastic surgery resident trained in France, Brazil, and the United States and a former elite rhythmic gymnast who won more than 30 Greek national titles and two bronze medals at the 2013 World School Championships. The company's framework was published in the peer-reviewed journal Cureus and is indexed on PubMed. BHI maintains a professional network across Beverly Hills, New York, Athens, London, Paris, and Sydney. Learn more at beautyhealthindex.com, or follow Dr. Korina Alevrogianni and Beauty Health Index on Instagram.

Disclaimer

The Beauty Health Index (BHI) framework and smartphone scanning application are intended solely for general aesthetic, wellness, and informational purposes and do not constitute a validated clinical diagnostic instrument or medical advice. The underlying methodology and ongoing validation studies have not been evaluated or cleared by the U.S. Food and Drug Administration (FDA) or other health regulatory authorities for the diagnosis, cure, mitigation, treatment, or prevention of any disease or medical condition. Individuals and medical practitioners should not rely on BHI scores as a substitute for professional clinical judgment, formal medical diagnosis, or personalized treatment planning.

Media Contact

Ana Gilvani
ana@beautyhealthindex.com